Proteasome inhibitor/imatinib combinations exert potentiated antileukemia efficacy but not cardiotoxicity in chronic myeloid leukemia (CPCI-S收录) | |
Zhou, Guangbiao[1]; Hu, Zheng[1]; Pan, Xiaofen[1]; Liu, Jinglei[1]; Ma, Liyuan[2]; Liu, Xiaoli[3]; Meng, Fanyi[3]; Li, Juan[4]; Chen, Zhu[2]; Chen, Saijuan | |
会议名称 | BLOOD |
URL标识 | 查看原文 |
内容类型 | 会议论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/2101489 |
专题 | 华南理工大学 |
作者单位 | 1.[1]Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Lab Mol Target Based Therapy Canc, Guangzhou, Guangdong, Peoples R China 2.[2]Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Hematol, Shanghai 200030, Peoples R China 3.[3]Nanfang Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Guangdong, Peoples R China 4.[4]Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou, Guangdong, Peoples R China |
推荐引用方式 GB/T 7714 | Zhou, Guangbiao[1],Hu, Zheng[1],Pan, Xiaofen[1],等. Proteasome inhibitor/imatinib combinations exert potentiated antileukemia efficacy but not cardiotoxicity in chronic myeloid leukemia (CPCI-S收录)[C]. 见:BLOOD. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论